Science Explorer Back to mapMap
Discussion
Company · Tromsø · Norway

Pharmasum Therapeutics (Norway)

pharmasum.comROR OpenAlex
Research works
1
▲ 52% vs 2018-21
Citations
25
17.7 per fractional work
Top-10% rate
5.3%
all institutions 10.0%
Open access
100%
world 40%
International
76%
world 18%
Pharmasum Therapeutics (Norway)

Not ranked overall: Pharmasum Therapeutics (Norway) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Pharmasum Therapeutics (Norway) work in?

In all years, 80% of research at Pharmasum Therapeutics (Norway) is in Health Sciences, 13% in Life Sciences. Its largest fields are Medicine (80%), Immunology and Microbiology (7%), Neuroscience (7%). It does 1.3× the world's share of Health Sciences.

Health Sciences: 1 fractional works · 80.0% of its workMedicine: 1 fractional works · 80.0% of its workLife Sciences: 0 fractional works · 13.3% of its workImmunology and Microbiology: 0 fractional works · 6.7% of its workNeuroscience: 0 fractional works · 6.7% of its workPhysical Sciences: 0 fractional works · 6.7% of its workChemistry: 0 fractional works · 6.7% of its workALL ITS WORKPharmasumTherapeutics…2fractional works, all years
Life Sciences13%Physical Sciences7%Health Sciences80%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 4 fields, with their numbers
    1. Medicine180.0%
    1. Immunology and Microbiology06.7%
    2. Neuroscience06.7%
    1. Chemistry06.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Pharmasum Therapeutics (Norway)?

The most cited paper from Pharmasum Therapeutics (Norway) is "Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules" (Ulli Rothweiler, Wenche Stensen, Bjørn Olav Brandsdal et al., 2016), with 46 citations. Next come "Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome" (19) and "DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes" (15).

Most cited papers
#PaperReleasedCitations
1 Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules Ulli Rothweiler, Wenche Stensen, Bjørn Olav Brandsdal et al. · Journal of Medicinal Chemistry Open access 13 Oct 2016 46
2 Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome Wenche Stensen, Ulli Rothweiler, Richard Alan Engh et al. · Pharmaceuticals Open access 17 Nov 2021 19
3 DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes Bangfu Zhu, Tom Parsons, Wenche Stensen et al. · Frontiers in Pharmacology Open access 19 Jul 2022 15
All 3 most cited papers, with filters and sorting

Which research topics does Pharmasum Therapeutics (Norway) publish most on?

By volume in 2022-now: Down syndrome and intellectual disability research, Alzheimer's disease research and treatments, Renal Diseases and Glomerulopathies and Antimicrobial Peptides and Activities.

Down syndrome and intellectual disability research: 0 fractional worksAlzheimer's disease research and treatments: 0 fractional worksRenal Diseases and Glomerulopathies: 0 fractional worksAntimicrobial Peptides and Activities: 0 fractional worksMicrobial Natural Products and Biosynthesis: 0 fractional worksRenin-Angiotensin System…0Renin-Angiotensin System Studies: 0 fractional worksChronic Kidney Disease and Diabetes: 0 fractional worksAntimicrobial agents and applications: 0 fractional works
Public Health, Environmental and Occupational HealthPhysiologyNephrologyMicrobiology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Down syndrome and intellectual disability research Public Health, Environmental and Occupational Health 0 works
  2. 2 Alzheimer's disease research and treatments Physiology 0 works
  3. 3 Renal Diseases and Glomerulopathies Nephrology 0 works
  4. 4 Antimicrobial Peptides and Activities Microbiology 0 works
  5. 5 Microbial Natural Products and Biosynthesis Pharmacology 0 works
  6. 6 Renin-Angiotensin System Studies Cardiology and Cardiovascular Medicine 0 works
  7. 7 Chronic Kidney Disease and Diabetes Nephrology 0 works
  8. 8 Antimicrobial agents and applications Organic Chemistry 0 works
  9. 9 Advanced Biosensing Techniques and Applications Molecular Biology 0 works
  10. 10 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available100.0%

World: 40% of research is openly available.

with international co-authors76.4%domestic only23.6%

World: 18% is written across borders.

How has Pharmasum Therapeutics (Norway)'s research output changed?

Output in 2022-2025 was 52% higher than in 2018-2021.

still counting20202025

Other research institutions in Tromsø

All research institutions in Tromsø

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Pharmasum Therapeutics (Norway). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.